Ozempic Market to Reach USD 24.8 Billion by 2035

According to analysts at Vantage Market Research, the Global Ozempic Market size is worth USD 10.85 Billion in 2024 and is projected to reach USD 24.8 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 7.8% from 2025 to 2035. Key trends of market include rising obesity treatments, expanded GLP-1 applications, increasing prescriptions, telehealth adoption, biosimilar development, direct-to-consumer marketing, supply chain challenges, and growing investment in diabetes and weight management solutions.

Market Overview

The global incidence of type 2 diabetes and obesity has been steadily increasing the demand for Ozempic drug, driven by a combination of lifestyle changes, urbanization, and dietary habits. Individuals with higher body fat are more susceptible to diabetes, prompting many to adopt preventive measures, including the use of anti-obesity treatment like Ozempic. According to the World Obesity Atlas 2023, over 4 billion people globally are projected to be overweight or obese (BMI ≥25kg/m²) by 2035, with obesity alone (BMI ≥30kg/m²) expected to affect nearly 2 billion individuals, including adults, children, and adolescents. Additionally, the WHO's May 2022 report highlights that in the European region, over 60% of adults and nearly 30% of children are overweight or obese, with these conditions ranking fourth among risk factors for non-communicable diseases. 

Ozempic has established itself as a highly effective treatment due to its dual-action benefits in glycemic control and weight management drives the ozempic market. It has been shown in clinical trials and empirical data to considerably reduce HbA1c levels, a crucial indicator of long-term glycemic control, and to significantly aid in weight loss. Ozempic is recommended option for patients and healthcare professionals for management of type 2 diabetes and obesity. Ozempic is strengthened by the ease of once-weekly dosage, which improves patient adherence. 

Novo Nordisk informed the Therapeutic Goods Administration

• In September 2023, Novo Nordisk informed the Therapeutic Goods Administration and the Ozempic Medicine Shortage Action Group that supply would be constrained for the remainder of 2023 and into 2024. The company noted a significant increase in demand, particularly for the lower-dose (0.25/0.5 mg) version, driven largely by a rapid rise in off-label prescriptions for conditions beyond the drug's approved uses

Key Takeaways from the Report

• North America dominated the market with 41.5% of market share in 2024.  Market is driven by a significant rise in diabetes prevalence over the past two decades
• Based on the Application, the Type 2 Diabetes Mellitus category accounted for significant market share in 2024. Ozempic is primarily indicated for managing type 2 diabetes, where it helps improve glycemic control in adults
• In 2024, by Route of Administration, Parenteral dominated the market with significant market share. The parenteral segment represents the only commercially available form of Ozempic
• Based on Distribution Channel, Retail Pharmacies dominated the market in 2024. The segment caters to the majority of patients who manage diabetes and obesity on an outpatient basis in Ozempic market

Top Companies

• Novo Nordisk

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

• November 2023: The German regulatory body, BfArM, is contemplating a ban on the export of Ozempic as European healthcare systems face shortages of the drug, which has seen a surge in demand due to its weight-loss effects